Fact.MR predicts the global sales of breast cancer diagnostics to surpass US$ 7.9 Bn by registering a CAGR of 7% in the forecast period 2022-2032. Demand for cost-effective, technologically advanced, efficient, and accurate diagnostic solutions is anticipated to be a major trend in the industry over the decade.

Historically, from 2017 to 2021, demand for breast cancer diagnostics flourished at a CAGR of 6%. Healthcare infrastructure all over the globe took a hit when coronavirus became a global pandemic in the first quarter of 2020. Every nation had to reassess their healthcare strategies, and this resulted in major reforms all across the globe. With rising prevalence of cancer cases all over the globe, demand from the general population for effective measures to treat and diagnose breast cancer increased, and governments are focusing on extensively providing these solutions in a cost-effective manner.

REQUEST FOR SAMPLE

Breast cancer diagnostics providers are focusing on developing new instruments and devices that facilitate the early detection of breast cancer, which is vital in combating the disease effectively. Investments in research are also anticipated to see a major increase over the next ten years as focus is on treating and combating breast cancer.

Key Takeaways from the Market Study

• By test type, CEA test expected to hold more than 45% market share for breast cancer diagnostics
• By end user, hospital based labs expected to hold more than 50% market share for breast cancer diagnostics market.
• Breast cancer diagnostics industry expected to possess nearly 45% market share throughout North America.
• Breast cancer diagnostics industry expected to possess nearly 40% market share throughout Asia Pacific.
• Global market for breast cancer diagnostics to reach US$ 4 Bn by the end of 2022

“Rising number of active breast cancer cases is a major concern across the globe, and non-existence of early diagnostic solutions is a major factor influencing the landscape,” says a Fact.MR analyst.

Early Detection Bolstering Demand for Breast Cancer Diagnostics?

The number of breast cancer cases across the globe is rising rapidly and has become the most common type of cancer in 2021. Early detection of breast cancer tumours is one of the major challenges in diagnosis and treatment, as in most cases, they are detected after they have grown to an advanced stage.

Demand for early detection of breast cancer is seeing a major rise as people are seeking more efficient diagnostic solutions to deal with the disease effectively. Apart from other tests to detect breast cancer, imaging and screening have also seen substantial rise in popularity. Screening for breast cancer is deemed effective, but some methods are still being debated whether they are safe and accurate for prolonged use.

Breast cancer diagnostic PCR tests, biopsy for breast cancer diagnostics, and application of microarray in breast cancer diagnostics are some of the trends that are expected to be witnessed over the decade.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com